Phase II Study For The Prevention Of Clinically Significant Adenovirus Adv, BK Virus BKV, Cytomegalovirus CMV, Epstein-Barr Virus EBV, Human Herpesvirus 6 HHV-6 And JC Virus JCV Infections Among Patients With No Viremia And/Or Disease In Patients With Detectable Viremia In Patients At High Risk For These Viruses Following Allogeneic Hematopoietic Cell Transplant HCT.

Brief Summary

Type:
Hematologic - Other

Study Type:
Treatment

Phase:
II

ClinicalTrials.gov Identifier:
NCT04693637

Study #:
Study00146620

Start Date:
May 20, 2021

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT04693637

View Complete Trial Details & Eligibility at ClinicalTrials.gov